Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients

Norbert Heinrich, Rodney Dawson, Jeannine du Bois, Kim Narunsky, Gary Horwith, Andrew J Phipps, Carol A Nacy, Rob E Aarnoutse, Martin J Boeree, Stephen H Gillespie, Amour Venter, Sonja Henne, Andrea Rachow, Patrick P J Phillips, Michael Hoelscher, Andreas H Diacon, Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA)

Research output: Contribution to journalArticlepeer-review

73 Citations (Scopus)

Abstract

SQ109, an asymmetrical diamine, is a novel anti-TB drug candidate. This first study in patients was done to determine safety, tolerability, pharmacokinetics and bacteriological effect of different doses of SQ109 alone and in combination with rifampicin when administered over 14 days.
Original languageEnglish
JournalJournal of Antimicrobial Chemotherapy
DOIs
Publication statusPublished - 27 Jan 2015

Fingerprint

Dive into the research topics of 'Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients'. Together they form a unique fingerprint.

Cite this